Cheminant M, Dreyling M, Hermine O. Recent advanced in the first-line treatment of mantle cell lymphoma. Ann Lymphoma 2020;4:2
Cohen JB, Zain JM, and Kahl BS. Current approach to mantle cell lymphoma: Diagnosis, prognosis and therapies. ASCO Educational Book 2017:512-525.
Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 (Supplement 4):iv62-iv71, 2017.
Elias Campo and Simon Rule. Mantle cell lymphoma: evolving management strategies. Blood 2015;125(1):48-55.
Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle-cell lymphoma. Blood 2008;111:558-565.
Ladha, A, Zhao J, Epner EM and Pu JJ. Mantle cell lymphoma and its management: where are we now? Exp Hematol Oncol 8, 2 (2019). https://doi.org/10.1186/s40164-019-0126-0
Le Gouill S, Beldi-Ferchiou A, Alcantara M, et al. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle-cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Hematol 2020; (published online Sept 21.)
Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010;115:3215-2323.
Witzens-Harig M, Hess G, Atta J, et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol (2012) 91:1765-1772.